Genezen Welcomes New Board Members to Propel Growth
Genezen takes a significant step forward in its mission as a leading gene therapy contract development and manufacturing organization (CDMO) by announcing two pivotal additions to its Board of Directors. The esteemed professionals, Dr. Pam Stetkiewicz and Stuart Auerbach, bring a wealth of experience that will undoubtedly enhance the company’s strategic direction.
Strengthening the Board with Industry Leaders
These recent appointments are part of Genezen's larger strategy to harness industry expertise during a transformative phase for the organization. With state-of-the-art facilities, including a recently expanded location, Genezen collaborates with innovative companies to facilitate the development and manufacturing of gene and cell therapies across the globe.
Dr. Pam Stetkiewicz's Contributions
Dr. Stetkiewicz’s arrival is particularly significant due to her invaluable experience in gene therapy development. As the Chief Operating Officer of Arbor Biotechnologies, she exemplifies leadership and innovation in the field of gene editing. Dr. Stetkiewicz’s previous roles at notable companies underscore her expertise, including positions at Flagship Pioneering, Editas Medicine, and Novartis. With her strong academic background, including a PhD in Immunology from Johns Hopkins University, she is well-prepared to contribute to Genezen's vision. Dr. Stetkiewicz expressed her enthusiasm by stating that she is eager to assist in propelling Genezen's growth forward.
Stuart Auerbach's Expertise
Bringing a unique perspective, Mr. Auerbach has three decades of experience working with founders to build successful ventures. His role as an investor and advisor in various CDMOs equips him with the insights necessary to guide Genezen in enhancing its operational efficiency. Currently a Senior Advisor at Ampersand Capital Partners, Mr. Auerbach’s academic credentials, including a B.S. in Chemical Engineering from Columbia University and an MBA from Harvard Business School, solidify his expertise. He noted that Genezen’s rapid emergence as a leader in the gene therapy space makes this an exciting time to be involved.
Vision for the Future
Steve Favaloro, Chairman and CEO of Genezen, highlighted the importance of these appointments to the company's ongoing development. He expressed that the wealth of experience brought by Pam and Stuart will be crucial as Genezen navigates through this dynamic period in the biotech landscape.
About Genezen
Genezen is a distinguished CDMO with a decade of experience in the industry. It operates with cutting-edge facilities tailored for viral vector manufacturing. Genezen’s commitment to innovation ensures that it can support various types of gene and cell therapies as they advance from conception to commercial distribution. The company prides itself on its flexible, customer-centric approach, allowing collaboration with organizations of all sizes—from academia to large multinational biopharma enterprises.
Frequently Asked Questions
1. Who are the new board members at Genezen?
The new board members are Dr. Pam Stetkiewicz and Stuart Auerbach, both of whom bring extensive experience in the gene therapy industry.
2. What expertise does Dr. Pam Stetkiewicz bring?
Dr. Stetkiewicz has a strong background in gene therapy drug development and holds a PhD in Immunology, currently serving as the COO of Arbor Biotechnologies.
3. How does Stuart Auerbach contribute to Genezen?
Mr. Auerbach offers decades of experience in scaling companies and has been involved in multiple successful ventures in the therapeutics and medical device sectors.
4. What is Genezen’s mission?
Genezen aims to be a leader in the gene therapy sector, developing and manufacturing therapies that save lives globally.
5. How does Genezen support its partners?
Genezen offers flexible, customer-focused programs tailored to each partner's needs, ensuring successful collaborations from early development to marketplace.
